Get started
Author

Laura Serwer

Observed names: L. P. Serwer, L. Serwer, Laura P Serwer, Laura P. Serwer
ORCID: 0000-0002-6296-0707
Observed ORCID: 0000-0002-6296-0707
OpenAlex ID: A5020819684
Challenges in drug delivery to tumors of the central nervous system: An overview of pharmacological and surgical considerations
2012 · Laura P. Serwer, C. David James · Advanced Drug Delivery Reviews · 114
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
2022 · Shweta Singh, Laura Serwer, et al. · Molecular Cancer Therapeutics · 41
PDF
Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
2010 · Laura Serwer, Rintaro Hashizume, et al. · Journal of Visualized Experiments · 40
Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts
2011 · L. P. Serwer, C. O. Noble, et al. · Neuro-Oncology · 29
PDF
Convection-Enhanced Delivery of Targeted Quantum Dot–Immunoliposome Hybrid Nanoparticles to Intracranial Brain Tumor Models
2013 · Kevin C Weng, Rintaro Hashizume, et al. · Nanomedicine · 25
Abstract ND02: CTX112 and CTX131: Next-generation CRISPR/Cas9-engineered allogeneic (allo) CAR T cells incorporating novel edits that increase potency and efficacy in the treatment of lymphoid and solid tumors
2023 · Jonathan A. Terrett, Demetrios Kalaitzidis, et al. · Cancer Research · 18
Abstract 17013: CTX320: An Investigational in vivo CRISPR-Based Therapy Efficiently and Durably Reduces Lipoprotein (a) Levels in Non-Human Primates After a Single Dose
2023 · Phuong Khanh Morrow, Sanjay D'Souza, et al. · Circulation · 13
Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
2010 · Laura Serwer, Rintaro Hashizume, et al. · Journal of Visualized Experiments · 9
PDF
Abstract B116: Optimizing a CD71-targeting Probody drug conjugate (PDC) for activity in multiple solid tumor and lymphoma models and for tolerability in nonhuman primates
2018 · Shweta Singh, Laura Serwer, et al. · Molecular Cancer Therapeutics · 5
O2.04 * Treatment With Omx-4.80, a Tumor-penetrating Tunable Oxygen Carrier, Reduces Tumor Hypoxia and Dramatically Enhances Radiation Therapy in Intracranial Models of Glioblastoma
2014 · A. Krtolica, N. Le Moan, et al. · Neuro-Oncology · 5
Abstract 16908: CTX310: An Investigational in vivo CRISPR-Based Therapy Efficiently and Durably Reduces ANGPTL3 Protein and Triglyceride Levels in Non-Human Primates After a Single Dose
2023 · Phuong Khanh Morrow, Yi-Shan Chen, et al. · Circulation · 3
Abstract B103: A multi-analyte HPLC-MS/MS approach to assessing exposure of a Probody drug conjugate in preclinical studies
2018 · Laura Serwer, Shweta Singh, et al. · Molecular Cancer Therapeutics · 3
ET-31 * RADIOSENSITIZATION BY OMX-4.80P, A PEGylated H-NOX OXYGEN CARRIER THAT PENETRATES AND OXYGENATES HYPOXIC TUMORS, IN PRECLINICAL MODELS OF GLIOBLASTOMA AND OTHER HYPOXIC CANCERS
2014 · A. Krtolica, N. Le Moan, et al. · Neuro-Oncology · 3
PDF
Experimental Therapeutics and Pharmacology
2013 · C. Aaberg-Jessen, L. Fogh, et al. · Neuro-Oncology · 3
PDF
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma
2026 · Joseph P. McGuirk, Armin Ghobadi, et al. · Blood Advances · 2
Abstract 3003: OMX-4.80P, a novel H-NOX oxygen carrier that oxygenates hypoxic tumors in multiple tumor models and canine cancer patients, downregulates HIF-1 pathway and increases response to radiation therapy leading to cures
2015 · Ana Krtolica, Natacha Le Moan, et al. · Cancer Research · 2
ET-32 * HYPOXIA REDUCTION IN INTRACRANIAL GLIOBLASTOMA MODELS BY OMX-4.80P, A PEGylated ENGINEERED H-NOX OXYGEN CARRIER THAT IS LONG-LASTING IN CIRCULATION AND SAFE
2014 · N. Le Moan, J. Getz, et al. · Neuro-Oncology · 2
274 Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CART cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency
2023 · Demetrios Kalaitzidis, Mohammed Ghonime, et al. · Regular and Young Investigator Award Abstracts · 1
PDF
Novel Oxygen Carrier Proteins, H-NOX, Reduce Tumor Hypoxia and Act as Radiosensitizers in an Orthotopic Mouse Model of Human Cancer
2012 · L. Serwer, E. Harris, et al. · International Journal of Radiation Oncology*Biology*Physics · 1
Preclinical Experimental Therapeutics and Pharmacology
2011 · H. Pavel, N. Ajeawung, et al. · Neuro-Oncology · 1
PDF
University of California Research Seminar Network: A Prospectus
2010 · James R. Carey, John Christian Laursen, et al. · PLoS Biology · 1
PDF
Supplementary Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
2023 · Shweta Singh, Laura Serwer, et al.
Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
2023 · Shweta Singh, Laura Serwer, et al.
Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
2023 · Shweta Singh, Laura Serwer, et al.
Preliminary single-dose clinical pharmacokinetics of an anti–PD-L1 Probody therapeutic (Pb-Tx) in cancer patients.
2018 · Mark Stroh, Laura Serwer, et al. · Journal of Clinical Oncology
Works count: 35
Citation count: 327
H-index: 8
I10-index: 7
Year
Topic
Type